Group 1: Iodine Applications and Market Overview - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, widely used in various product formulations as key components or catalysts [2] - The downstream application structure of iodine includes three core areas: X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing, collectively accounting for approximately 63% of global consumption [2] - Major iodine production is concentrated in three regions: Chile, Japan, and the United States, which together account for 88% of global sales [2] Group 2: Iodine Production and Market Share - Five companies in Chile account for about 60% of global iodine sales, with SQM alone representing approximately 37% [2] - Eight Japanese producers collectively hold around 23% of the market share, while U.S. producers account for nearly 5% [2] - Other countries with minor production include Russia, Turkmenistan, Azerbaijan, Indonesia, and China [3] Group 3: Company Product Offerings - The company’s inorganic iodide products include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, primarily used in pharmaceuticals, pesticides, feed, and optoelectronic materials [3] - The company’s organic iodide product, trimethylsilyl iodide, serves as a protecting group in organic synthesis, mainly applied in pharmaceutical production (e.g., cephalosporins, macrolide antibiotics) [3] - The company has a 4,000 tons/year inorganic iodide production project focusing on potassium iodide, hydriodic acid, ammonium iodide, silver iodide, and lithium iodide [3]

Core Viewpoint - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., is engaged in the research, production, and sales of fine chemicals, with a focus on iodine compounds and precious metal catalysts, showing a mixed financial performance in recent periods [2]. Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2]. - The company specializes in fine chemical products, including organic and inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The revenue composition of the company includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 747 million yuan, representing a year-on-year growth of 7.39% [2]. - The net profit attributable to the parent company was 99.04 million yuan, which reflects a year-on-year decrease of 19.09% [2]. - As of September 19, the number of shareholders increased to 10,300, with an average of 3,233 circulating shares per person, a decrease of 1.00% from the previous period [2]. Group 3: Market Activity - On September 22, the company's stock rose by 1.41%, with a trading volume of 284 million yuan [1]. - The financing buy-in amount for the company on the same day was 23.83 million yuan, while the financing repayment was 36.46 million yuan, resulting in a net financing buy-in of -12.63 million yuan [1]. - The total margin trading balance for the company as of September 22 was 113 million yuan, accounting for 4.39% of the circulating market value [1].

证券代码：301617 证券简称：博苑股份 公告编号：2025-048 山东博苑医药化学股份有限公司 关于部分募投项目变更后新签订募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1415 号）同意注册，山东博苑 医药化学股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股） 股票 2,570.00 万股，每股面值 1 元，每股发行价格为人民币 27.76 元。本次发行 募集资金总额为 71,343.20 万元，扣除发行费用 8,526.43 万元（不含税）后，募 集资金净额为 62,816.77 万元。募集资金已于 2024 年 12 月 5 日划至公司指定账 户，天健会计师事务所（特殊普通合伙）对公司募集资金的到位情况进行了审验， 并出具了天健验〔2024〕494 号《验资报告》。公司依照相关规定对募集资金的 存放和使用进行专户管理，并与保荐人及存放募集资金的商业银行签署了《募集 资金 ...

Group 1 - The company, Boyuan Co., Ltd. (301617), reported that as of September 10, 2025, the total number of shareholders is 10,228 [1]

Core Viewpoint - The company is currently constructing a 4,000 tons/year inorganic iodide production project, and the lithium iodide product has not yet reached mass production [1] Group 1 - The inorganic iodide production project is in the construction phase [1] - The lithium iodide product's production and sales status will be disclosed in future periodic reports [1]

Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has shown significant price increases this year, with a year-to-date rise of 108.17% as of September 15, 2023, despite a recent decline in trading [1][2]. Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2]. - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The revenue composition of the company includes 74.56% from iodides, 12.79% from specialty functional chemicals, 9.94% from trading, and 2.72% from other sources [2]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 747 million yuan, representing a year-on-year growth of 7.39%, while the net profit attributable to shareholders decreased by 19.09% to 99.04 million yuan [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. Group 3: Stock Performance and Trading Activity - As of September 15, 2023, the stock price was 80.64 yuan per share, with a market capitalization of 10.777 billion yuan [1]. - The stock has experienced a trading volume of 1.17 billion yuan, with a turnover rate of 4.25% [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent net buy of 51.18 million yuan on September 9, 2023 [1].

Group 1 - The company announced on September 12 that its existing inorganic iodides include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, which are primarily used in pharmaceuticals, pesticides, animal feed, and optoelectronic materials [1] - The company's organic iodide product, trimethyl iodide silane, serves as a functional group protecting agent in organic synthesis, mainly applied in the pharmaceutical field, such as the production of cephalosporins and macrolide antibiotics [1]

Core Viewpoint - The company is expanding its business into hexamethyldisilazane products based on the common needs of its existing pharmaceutical clients and its advantages in resource utilization and technology [1] Group 1: Business Expansion - The company has identified a demand from its existing pharmaceutical clients for hexamethyldisilazane products, leading to its business expansion in this area [1] - The expansion into hexamethyldisilazane requires minimal additional investment and offers cost advantages in raw material acquisition [1] Group 2: Resource Utilization - The company has established a collaborative foundation in resource utilization, including operational qualifications, incineration facilities, shared equipment, production sites, practical experience, and a professional team [1] - The company is leveraging its strengths in waste recovery to extend its operations from organic solvent recovery to the recycling of siloxanes [1] Group 3: Market Positioning - Both iodides and hexamethyldisilazane are functional additives used in the pharmaceutical chemical process, sharing similar application scenarios and functional characteristics [1] - The company is strategically positioning itself in the market by utilizing its existing iodide products as a basis for the new hexamethyldisilazane product line, aligning with market demand and competitive landscape [1]

New Stock Issuance - YouSheng Co., Ltd. (Securities Code: 732418) issued shares at a price of 46.36 RMB on September 12, 2025[1] - *ST Tianmao (Securities Code: 000627) has a cash option declaration period from September 15 to September 19, 2025[1] - *ST Zitian (Securities Code: 300280) enters the delisting arrangement period starting September 15, 2025[1] Trading Alerts - Hangke Technology (Securities Code: 688006) reported severe abnormal fluctuations on September 11, 2025[1] - Shanghai Electric Power (Securities Code: 600021) had a trading volume of 8,487 on September 10, 2025[1] - Tianji Co., Ltd. (Securities Code: 002759) reported a trading volume of 8,705 on September 10, 2025[1] Abnormal Fluctuations - ST Lingnan (Securities Code: 002717) reported a trading volume of 7,965 on September 10, 2025[3] - ST Huaxi (Securities Code: 002630) reported a trading volume of 9,579 on September 11, 2025[3] - ST Jianye (Securities Code: 600381) reported a trading volume of 5,420 on September 3, 2025[3]

Group 1: Company Overview - The company is Shandong Boyuan Pharmaceutical Chemical Co., Ltd., with stock code 301617 and abbreviation Boyuan Shares [1]. - The investor relations activity took place on September 11, 2025, in the Boyuan Shares conference room [2]. Group 2: Key Products and Applications - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, widely used in various product formulations [2]. - The downstream application structure of iodine includes three core areas: X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing, which together account for approximately 63% of global consumption [2]. - Major iodine production is concentrated in Chile, Japan, and the USA, with these three countries expected to account for 88% of global production [3]. Group 3: Product Specifics - The company’s inorganic iodide products include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, primarily used in pharmaceuticals, pesticides, feed, and optoelectronic materials [4]. - The company’s organic iodide product, trimethylsilyl iodide, is used as a protecting group in organic synthesis, particularly in the production of antibiotics [4]. Group 4: Business Development and Future Plans - Currently, the company has not achieved sales in the solid-state battery sector but is exploring new application scenarios and conducting feasibility studies [4]. - The expansion into hexamethyldisilazane products is driven by existing pharmaceutical customer needs and the company's resource utilization capabilities [5]. - The company leverages its expertise in waste recovery to develop hexamethyldisilazane products, which share similar application scenarios and functional characteristics with iodides [5].